Subject
Histology,Physiology,Endocrinology, Diabetes and Metabolism
Reference25 articles.
1. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption;Muhlbauer;J. Bone Miner. Res.,1991
2. Structure–activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates;Dunford;J. Pharmacol. Exp. Ther.,2001
3. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study;Eisman;J. Rheumatol.,2008
4. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2year results from the MOBILE study;Reginster;Ann. Rheum. Dis.,2006
5. Clinical efficacy on fracture risk and safety of 0.5mg or 1mg/month intravenous ibandronate versus 2.5mg/day oral risedronate in patients with primary osteoporosis;Nakamura;Calcif. Tissue Int.,2013